The 340B Drug Pricing Program is an instrumental tool in ending the HIV and STD epidemics, enabling sexual health programs to expand and improve services, address health equity, and reduce health disparities. The 340B Program provides covered entities with up-front cost savings on medications, as well as the potential to generate revenue in the form of insurance payments, providing sexual health programs with valuable resources. Cost savings and revenue are reinvested back into sexual health services, expanding programmatic reach, and stretching scarce resources as far as they can go to end the HIV and STD epidemics.
Ending the HIV Epidemic Part C Clinics along with STD clinics who receive support from federal HIV, STD, and viral hepatitis grants are eligible for the 340B Drug Pricing Program, and NCSD is providing templates, toolkits, and technical assistance to support STD and sexual health clinics in leveraging the 340B Drug Pricing Program to support their efforts in ending the epidemics.